What was the outcome of the advisory vote on executive compensation?

The advisory vote to approve the compensation of CVS Health's named executive officers was not approved by shareholders. This indicates a lack of support for the executive compensation packages as disclosed in the proxy statement.

Were there any major changes to shareholder rights or governance proposed that were approved?

Two stockholder proposals related to governance were presented and both failed to be approved. These included a proposal to reduce the ownership threshold to request a stockholder action by written consent and a proposal regarding an independent Board Chair.

What impact does the approval of the Incentive Compensation Plan and Employee Stock Purchase Plan amendments have?

The approval of these amendments allows CVS Health to increase the number of shares available for issuance under its 2017 Incentive Compensation Plan and for sale under its 2007 Employee Stock Purchase Plan. This generally supports management's ability to use equity as a form of compensation and employee incentives.

How significant was the shareholder turnout at the Annual Meeting?

A quorum was met with the holders of 1,113,218,231 shares of common stock present, either in person or by proxy, representing a substantial portion of the outstanding shares.

CVS 8-K: Shareholder Matters

Summary

This 8-K filing from CVS Health Corporation details the voting results from its Annual Meeting of Stockholders held on May 14, 2020. The key takeaway for investors is the outcome of several critical proposals. All director nominees were overwhelmingly elected, and the appointment of Ernst & Young LLP as the independent registered public accounting firm was ratified. Additionally, proposals to amend the 2017 Incentive Compensation Plan and the 2007 Employee Stock Purchase Plan were approved, indicating shareholder support for management's proposed adjustments to equity-based compensation frameworks. However, a notable point is the advisory vote on executive compensation, which was *not* approved by shareholders. This signals potential dissatisfaction with the compensation packages for named executive officers. Both stockholder proposals presented, one on reducing ownership thresholds for written consent actions and another on an independent Board Chair, also failed to gain majority support. Investors should monitor any management response to the executive compensation outcome.

Key Highlights

1All 13 director nominees were elected to the Board of Directors with significant support.
2The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2020 was ratified by shareholders.
3Shareholders approved amendments to the 2017 Incentive Compensation Plan to increase authorized shares.
4Shareholders approved amendments to the 2007 Employee Stock Purchase Plan to increase available shares for sale.
5In an advisory vote, shareholders *did not approve* the compensation of the Company's named executive officers.
6Two separate stockholder proposals, concerning written consent thresholds and an independent Board Chair, were not approved.

CVS HEALTH Corp 8-K Report, Shareholder Vote Results (May 19, 2020)

Summary

Key Highlights

Frequently Asked Questions